Author: Editor

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, explains the different therapeutic needs of younger and older patients with acute myeloid leukemia, which is recognised as a clinically heterogeneous disease.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the upcoming International Workshop on Chronic Lymphocytic Leukaemia (iwCLL) in New York, NY, during May 2017. The themes of the iwCLL will highlight the latest advances in the management of chronic lymphocytic leukemia CLL, including the treatment of relapsed disease; optimization of treatment combinations; understanding of molecular changes in tumor cells; and clinically meaningful interactions within the tumor microenvironment.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses the rapidly changing treatment landscape of chronic lymphocytic leukemia, including the development of new venetoclax-based combinations with improved treatment efficacy.

Immunotherapy is personalized therapy for people with cancer–but can it outsmart CLL? Experts Drs. John Gribben, Constantine Tam,and William Wierda, along with Patient Power Founder Andrew Schorr, review immunotherapy advances and how they could impact CLL treatment.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Michael Hallek, MD, from the University of Cologne, Cologne, Germany, discusses chemotherapy, kinase inhibitors and ongoing research of personalised approaches for the treatment of patients with chronic lymphocytic leukemia.

Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma

Tony Choueiri, MD of Dana Farber discusses CheckMate 025 phase III trial at ASCO GU 2016

Robert Dreicer, MD of the University of Virginia Health System discusses immunotherapy in non muscle invasive bladder cancer at ASCO GU 2016.

Robert Dreicer, MD of the University of Virginia Health System discusses the how soon should we expect approval of immunotherapy in urothelial cancer at ASCO GU 2016.

Robert Dreicer, MD of the University of Virginia Health System discusses the future role of immunotherapy and checkpoint inhibitors in urothelial cancer at ASCO GU 2016.

Robert Dreicer, MD of the University of Virginia Health System discusses how Atezolizumab shows very significant activity in advanced urothelial cancer at ASCO GU 2016.

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA, gives an overview of the interim analysis of a multicenter prospective Phase II study of Dose-Adjusted EPOCH-R (NCT01092182), which showed that the vast majority of patients with Burkitt’s Lymphoma achieved complete remission with the DA-EPOCH-R based therapy. The results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from the University of Cologne, Cologne, Germany, evaluates current and emerging approaches for managing patients with multiple myeloma, including drug sequencing and a clinical trial investigating lenalidomide, bortezomib, dexamethasone and elotuzumab as induction therapy for newly diagnosed patients.

Monoclonal antibodies have been recognised for their significant potential in the treatment of multiple myeloma. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Christof Scheid, MD, PhD, from University of Cologne, Cologne, Germany, reviews the clinical development of elotuzumab, which targets CS1, and daratumumab, which targets CD38.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Dirk Reinhardt, MD, PhD, from Essen University Hospital, Essen, Germany, reviews the role of recent advances in the understanding of the biology of acute myeloid leukemia in children for the development of new therapeutic approaches.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from University Hospital of Göttingen, Göttingen, Germany, discusses significant advances in the treatment of lymphoma, including approaches that decrease the toxicity and increase the efficacy of chemotherapy; and approaches that reduce the use of chemotherapy, such as monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapy.

Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Martin Schrappe, MD, PhD, from University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany, explains that there have been significant advances in the understanding of pediatric ALL subtypes and there is now a need to define the clinical importance of these subtypes.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Lorenz Trümper, MD, from University Hospital of Göttingen, Göttingen, Germany, reviews the development of more tailored approaches for the treatment of lymphoma that have improved outcomes in patients.

Progress in the field of blood cancers has resulted in the rapid development of more effective, less toxic therapies. At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, discusses some of the challenges posed by the rising cost of treatments.

At the German Cancer Congress 2016, held in Berlin, Germany, from 24 to 27 February 2016, Rüdiger Hehlmann, MD, from Heidelberg University, Heidelberg, Germany, examines the recent progress in the treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL) and myelodyplastic syndrome (MDS).

At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany, discusses the development of treatment guidelines for patients with metastatic melanoma, including the challenges and next steps of applying the results from recent clinical trials into daily practice. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

What are monoclonal antibodies, and how are they used to treat CLL? From MD Anderson Cancer Center, Drs. Zeev Estrov and Michael Keating describe the function and properties of antibodies. As Dr. Keating says, Antibodies are key elements in everything we do in CLL because eventually most patients will develop significantly low levels of the normal gamma globulins. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole Lamanna explore the strategies of various checkpoint inhibitors and CAR-T cell therapies and how they work in a balancing act between both suppressing and stimulating your immune system. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Are you refractory to some of the existing myeloma medications? Are you a relapsed patient? Myeloma experts Drs. John Burke, Faith Davies and Noopur Raje along with patient advocate, Jack Aiello, gathered at the 2015 American Society of Hematology (ASH) meeting for a discussion covering subjects of maintenance treatment until progression to deepen response and achieve MRD negativity, creative uses of combination therapy, and specific clinical trials, all aimed to improve relapsed and refractory patients quality and quantity of life. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower…

Understanding all of the emerging immunotherapy options for CLL patients can be difficult. Drs. Zeev Estrov, Michael Keating, and Nicole Lamanna explore the strategies of various checkpoint inhibitors and CAR-T cell therapies and how they work in a balancing act between both suppressing and stimulating your immune system. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo

Guillermo De Velasco, MD at Dana Farber discusses discontinuing VEGF-TT for progression versus toxicity impacts outcomes of second-line therapies in mRCC at ASCO GU 2016

Dr. Petros Grivas, MD at Cleveland Clinic discusses how genomics in urothelial carcinomas may play much bigger role in the future at ASCO GU 2016

Dr. Petros Grivas, MD at Cleveland Clinic discusses inhibiting autophagy in bladder cancer at ASCO GU 2016

Dr. Petros Grivas, MD at Cleveland Clinic discusses clinical and pathological factors that can influence outcomes in upper tract urothelial cancer at ASCO GU 2016

Dr. Petros Grivas, MD at Cleveland Clinic discusses if treatment for prior cancer develops secondary bladder cancer at ASCO GU 2016

Marin Xavier, MD of the Scripps Health discusses the greatest impact of immune checkpoint inhibitors in hematologic malignancies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Marin Xavier, MD of the Scripps Health discusses the management of hematologic and solid tumor malignancies with PD-1 and PD-L1 monoclonal antibodies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Marin Xavier, MD of the Scripps Health discusses the most common adverse events for PD-1 and PD-L1 monoclonal antibodies at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Marin Xavier, MD of the Scripps Heal;th discusses her real world experience with the novel immune checkpoint inhibitors at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

At the German Cancer Congress 2016, held in Berlin, Germany from 24 February to 27 February 2016, Axel Hauschild, MD, from University of Kiel, Kiel, Germany, explains that the treatment of metastatic melanoma has been revolutionised by recent developments in immunotherapeutic agents, including ipilimumab, an anti-CTLA-4 antibody, pembrolizumab, an anti-PD-1 antibody, and nivolumab, an anti-PD-1 antibody; targeted agents, including vemurafenib and dabrafenib, both BRAF inhibitors; and the oncolytic virus immunotherapy, talimogene laherparepvec (T-VEC). European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews

Josep-Maria Ribera, MD, PhD from the Germans Trias i Pujol University Hospital, Barcelona, Spain, presents preliminary data, which shows that adult patients with high risk (HR) acute lymphoblastic leukemia (ALL) with an adequate minimal residual disease (MRD) response, can be safely managed without allogeneic hematopoietic stem cell transplantation (alloHSCT). He further explains why avoiding alloHSCT can be of advantage to the patients. The preliminary results are from the Pethema ALL-HR-11 trial presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

Tanguy Seiwert, MD of the University of Chicago discusses using biomarkers in Immunotherapy in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Tanguy Seiwert, MD of the University of Chicago discusses Pembrolizumab and nivolumab Immunotherapies and that they Show Efficacy in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Tanguy Seiwert, MD of the University of Chicago discusses Immunotherapy and how it is well tolerated in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Tanguy Seiwert, MD of the University of Chicago discusses immunotherapy and future use of combination treatment in Head and Neck Cancer at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Susan M. O’Brien, MD of University of California Irvine discusses Venetoclax in the management of CLL and where in the therapeutic algorithm it should play a role at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Susan M. O’Brien , MD of University of California Irvine the preferred treatment regimen for patients who fail frontline therapy in CLL at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Susan M. O’Brien, MD of University of California Irvine the preferred salvage regimens for Ibrutinib and Idelalisib-Rituximab at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Susan M. O’Brien, MD of University of California Irvine discusses the preferred frontline regimen for new CLL patients greater than 70 years at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Susan M. O’Brien, MD of University of California Irvine discusses how to decide between Ibrutinib and Idelalisib-Rituximab in relapse setting at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Susan M. O’Brien, MD of University of California Irvine discusses FCR produces better and longer progression free survival than BR at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Susan M. O’Brien, MD of University of California Irvine discusses Duvelisib and other PI3K inhibitors in CLL at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego.

Susan M. O’Brien, MD of University of California Irvine discusses Acalabrutinib, ONO-4059 and other novel BTK inhibitors in CLL at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Omid Hamid, MD of The Angeles Clinic discusses the future of Immunotherapy new developments and new clinical trials at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer

Omid Hamid, MD of The Angeles Clinic discusses how important it is in Immunotherapy to find the correct biomarkers at Scripps Health 36th Annual Conference: Clinical Hematology and Oncology in San Diego. www.scrippshealth.org/cancer